XSHE
002826
Market cap413mUSD
Jun 06, Last price
16.21CNY
1D
9.97%
1Q
57.23%
Jan 2017
-38.32%
IPO
68.85%
Name
Tibet Aim Pharm Inc
Chart & Performance
Profile
Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 667,039 -22.14% | 856,734 18.10% | |||||||
Cost of revenue | 583,311 | 789,287 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 83,728 | 67,447 | |||||||
NOPBT Margin | 12.55% | 7.87% | |||||||
Operating Taxes | 7,874 | 10,587 | |||||||
Tax Rate | 9.40% | 15.70% | |||||||
NOPAT | 75,854 | 56,860 | |||||||
Net income | 15,386 -65.14% | 44,135 3.91% | |||||||
Dividends | (20,281) | (19,007) | |||||||
Dividend yield | 0.89% | 0.98% | |||||||
Proceeds from repurchase of equity | (22) | (2,642) | |||||||
BB yield | 0.00% | 0.14% | |||||||
Debt | |||||||||
Debt current | 11,011 | 50,051 | |||||||
Long-term debt | |||||||||
Deferred revenue | 6,604 | 4,432 | |||||||
Other long-term liabilities | 1,862 | ||||||||
Net debt | (417,413) | (271,231) | |||||||
Cash flow | |||||||||
Cash from operating activities | 166,881 | 68,453 | |||||||
CAPEX | (3,181) | ||||||||
Cash from investing activities | (43,002) | ||||||||
Cash from financing activities | (59,303) | 27,592 | |||||||
FCF | 133,411 | 115,859 | |||||||
Balance | |||||||||
Cash | 385,856 | 321,283 | |||||||
Long term investments | 42,567 | 1 | |||||||
Excess cash | 395,071 | 278,446 | |||||||
Stockholders' equity | 517,398 | 517,316 | |||||||
Invested Capital | 372,603 | 512,273 | |||||||
ROIC | 17.14% | 10.48% | |||||||
ROCE | 10.91% | 8.53% | |||||||
EV | |||||||||
Common stock shares outstanding | 192,331 | 190,678 | |||||||
Price | 11.87 16.49% | 10.19 -6.94% | |||||||
Market cap | 2,282,969 17.50% | 1,943,006 -6.71% | |||||||
EV | 1,870,598 | 1,676,477 | |||||||
EBITDA | 107,864 | 90,148 | |||||||
EV/EBITDA | 17.34 | 18.60 | |||||||
Interest | 1,178 | 811 | |||||||
Interest/NOPBT | 1.41% | 1.20% |